ClinicalTrials.gg
CompletedNCT05399459Updated Mar 7, 2025Results posted

Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)

A Phase 3 interventional study of Rimegepant 25 MG and Rimegepant 75 MG in Migraine, sponsored by Pfizer. Completed at 50 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-07.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
897
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.

Enrollment
11th of 32
897 · median 618
Started
2022
with 7 others
Phase 3
14 of 32
5 open now
Registered
15th of 32
by date
Lead sponsor
24 of 32
Pfizer

Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 11th largest by enrollment, is one of 8 that started in 2022, is one of 14 in phase 3, and was the 15th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About rimegepant

rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing rimegepant in Migraine Disorders, or all of them as a file.
02

Study summary

This study is being conducted to determine the appropriate dose of rimegepant in Japanese subjects, as well as to evaluate the efficacy, safety, and tolerability of rimegepant in Japanese subjects for the acute treatment of migraine.

03

Conditions studied

  • Migraine

Keywords

  • Migraine
  • Headache
  • Acute Migraine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subject has at least 1 year history of migraines (with or without aura), consistent with a diagnosis according to the International Classification of Headache Disorder, 3rd Edition, including the following:

  1. Migraine attacks present for more than 1 year with the age of onset prior to 50 years of age.
  2. Migraine attacks, on average, lasting about 4-72 hours if untreated.
  3. Not more than 8 attacks of moderate to severe intensity per month within the last 3 months.
  4. Ability to distinguish migraine attacks from tension/cluster headaches.
  5. Consistent migraine headaches of at least 2 migraine headache attacks of moderate or severe intensity in each of the 3 months prior to Screening Visit and maintains this requirement during the Screening period.
  6. Less than 15 days with headache (migraine or non-migraine) per month in each of the 3 months prior to Screening Visit and maintains this requirement during the Screening Period.
  7. Subjects on prophylactic migraine medication are permitted to remain on therapy if the dose has been stable for at least 3 months prior to the Screening Visit, and if the dose is not expected to change during the course of the study.
  8. Subjects with for use of triptans may be included provided they meet all other study entry criteria.

Exclusion criteria

Exclusion Criteria:

  1. Subject has a history of migraine with brainstem aura (basilar migraine), hemiplegic migraine or retinal migraine.
  2. History of use of analgesics (e.g. nonsteroidal anti-inflammatory drugs [NSAIDs] or acetaminophen) on ≥ 15 days per month during the 3 months (12 weeks) prior to the Screening Visit.
  3. Subject history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Subjects with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or (TIA) during the 6 months prior to screening.
  4. Uncontrolled hypertension or uncontrolled diabetes (however subjects can be included who have stable hypertension and/or diabetes for at least 3 months prior to screening).
  5. Subject with other pain syndromes, psychiatric conditions, dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, interfere with study assessments.
  6. Subject has a history of gastric, or small intestinal surgery (including Gastric Bypass, Gastric Banding, Gastric Sleeve, Gastric Balloon, etc.), or has a disease that causes malabsorption.
  7. The subject has a history or current evidence of any unstable medical conditions (e.g., history of congenital heart disease or arrhythmia, known or suspected infection, or C, or cancer) that, in the investigator's opinion, would expose them to undue risk of a significant adverse event (AE) or interfere with assessments of safety or efficacy during the course of the trial.
  8. History of alcohol abuse and/or illicit drug use meeting criteria for substance use disorder within 6 months of screening.
  9. Participation in any other clinical trial while participating in this clinical trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
897 participants (actual)

Study arms

  • Experimental
    Rimegepant 25 mg

    Single dose of 25 mg orally disintegrating tablet of rimegepant

    Drug: Rimegepant 25 MG

  • Experimental
    Rimegepant 75 mg

    Single dose of 75 mg orally disintegrating tablet of rimegepant

    Drug: Rimegepant 75 MG

  • Placebo comparator
    Placebo

    Matching placebo tablet

    Drug: Placebo

Interventions

  • Single dose of 25 mg orally disintegrating tablet of rimegepant

    Also known as: BHV3000

  • Single dose of 75 mg orally disintegrating tablet of rimegepant

    Also known as: BHV3000

  • DrugPlacebo

    Matching placebo tablet

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Had Freedom From Pain at 2 Hours Post-Dose

    Pain freedom at 2 hours post-dose was defined as having a pain intensity of none at that time point. Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (no pain) were considered to have freedom from pain. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in Statistical Analysis Plan (SAP).

    Time frame: 2 hours post-dose

Secondary outcomes

  1. Percentage of Participants With Pain Relief at 2 Hours Post-Dose

    Pain relief at 2 hours post-dose was defined as a pain intensity of none or mild at that time point. Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

    Time frame: 2 hours post-dose

  2. Percentage of Participants Who Had Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-Dose

    MBS freedom was defined as MBS reported before dosing that was absent post-dose. MBS included nausea, photophobia, or phonophobia. MBS were measured using a binary scale as 0= absent, 1= present. Participants who had score of 0 (MBS absent) were considered to have freedom from MBS. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

    Time frame: 2 hours post-dose

  3. Percentage of Participants With Ability to Function Normally at 2 Hours Post-Dose

    Functional disability was defined as a functional disability level of mildly impaired, severely impaired, or required bedrest. Participants rated the level of disability they perceived as a result of their migraine in performing normal actions using following level of severity: normal function, mild impairment, severe impairment, or required bedrest. Percentage of participants with a response of "normal function" at the 2 hours post-dose were reported in this outcome measure. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

    Time frame: 2 hours post-dose

  4. Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-Dose

    Sustained Pain relief from 2 to 24 hours post-dose was defined as a pain intensity of none or mild at all time points from 2 to 24 hours post-dose. Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (with no pain) through 2 to 24 hours post-dose were considered to have sustained pain relief. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

    Time frame: 2 to 24 hours post-dose

  5. Percentage of Participants Who Used Rescue Medication Within 24 Hours Post-Dose

    Percentage of participants who used rescue medications within 24 hours of administration of study drug were reported in this outcome measure. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

    Time frame: Within 24 hours post-dose

  6. Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-Dose

    Sustained pain relief from 2 to 48 hours post-dose was defined as a pain intensity of none or mild at all time points from 2 to 48 hours post-dose. Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (with no pain) through 2 to 48 hours post-dose were considered to have sustained pain relief. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

    Time frame: 2 to 48 hours post-dose

  7. Percentage of Participants With Absence of Photophobia at 2 Hours Post-Dose

    Photophobia (sensitivity to light) status was measured as absent or present in the electronic diary (eDiary). Freedom from photophobia was defined as photophobia absent. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

    Time frame: 2 hours post-dose

  8. Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-Dose

    Sustained pain freedom from 2 to 24 hours post-dose was defined as a pain intensity of none at all time points from 2 to 24 hours post-dose. Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (with no pain) through 2 to 24 hours post-dose were considered to have sustained pain freedom. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

    Time frame: 2 to 24 hours post-dose

  9. Percentage of Participants With Freedom of Phonophobia at 2 Hours Post-Dose

    Phonophobia (sensitivity to sound) status was measured as absent or present in the eDiary. Freedom from phonophobia was defined as phonophobia absent. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

    Time frame: 2 hours post-dose

  10. Percentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-Dose

    Sustained pain freedom from 2 to 48 hours post-dose was defined as a pain intensity of none at all time points from 2 to 48 hours post-dose. Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (with no pain) through 2 to 48 hours post-dose were considered to have sustained pain freedom. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

    Time frame: 2 to 48 hours post-dose

  11. Percentage of Participants With Freedom From Nausea at 2 Hours Post Dose

    Nausea status was measured as absent or present in the eDiary. Freedom from nausea was defined as nausea absent. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

    Time frame: 2 hours post-dose

  12. Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-Dose

    Pain relapse from 2 to 48 hours post-dose was defined as pain intensity of mild, moderate, or severe at any time point post-dose after 2 hours post-dose for the subset of participants with pain intensity of none at 2 hours post-dose. Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eDiary. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

    Time frame: 2 to 48 hours post-dose

  13. Number of Participants With Adverse Events (AEs) by Intensity

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. AE intensity included mild, moderate and severe. Mild AE is defined as AEs which is usually transient and may require only minimal treatment or therapeutic intervention. The event were not generally interfered with usual activities of daily living. Moderate AE is defined as AEs which is usually alleviated with additional specific therapeutic intervention. The event interfered with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the participants. Severe AE is defined as AE that interrupts with usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.

    Time frame: From the day of signing informed consent up to end of treatment visit (approximately maximum up to 11 weeks)

  14. Number of Participants With Serious AEs

    A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect in the off spring who received rimegepant were considered an important medical event.

    Time frame: From the day of signing informed consent up to end of treatment visit (approximately maximum up to 11 weeks)

  15. Number of Participants With Grade 3 to 4 Laboratory Test Abnormalities- Hematology

    Laboratory test abnormalities in hematology included: Eosinophils, Hemoglobin (high, low), Lymphocytes (high, low), Neutrophils, Platelets, White blood cell count (high, low). Laboratory abnormality events were graded according to National Cancer Institute Common Terminology Criteria For Adverse Events (NCI CTCAE) v5.0; grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening consequences and grade 5=death. Number of participants who had hematology parameter abnormality Grade 3 to 4 are reported in this outcome measure. Number of participants with non-zero laboratory abnormalities were reported in this outcome measure.

    Time frame: Baseline (Day 1) up to End of treatment visit (within 7 days of treatment) [approximately maximum up to 7 weeks]

  16. Number of Participants With Grade 3 to 4 Laboratory Test Abnormalities- Serum Chemistry

    Laboratory test abnormalities in serum chemistry included: alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, Bilirubin (total), calcium (high, low), cholesterol (total), creatine kinase, creatinine, estimated glomerular filtration rate (eGFR), Modification of Diet in Renal Disease (MDRD), glucose, (high, low), lactate dehydrogenase low density lipoprotein (LDL) cholesterol (fasting, non-fasting), potassium (high, low), sodium (high, low), triglycerides (fasting, non-fasting), uric acid. Laboratory abnormality events were graded according to NCI CTCAE v5.0; grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening consequences and grade 5=death. Number of participants who had serum chemistry parameter abnormality Grade 3 to 4 are reported in this outcome measure. Number of participants with non-zero laboratory abnormalities are reported in this outcome measure.

    Time frame: Baseline (Day 1) up to End of treatment visit (within 7 days of treatment) [approximately maximum up to 7 weeks]

  17. Number of Participants With Grade 3 to 4 Laboratory Test Abnormalities- Urinalysis

    Laboratory test abnormalities in urinalysis included: Urine glucose, Urine protein, pH, specific gravity, ketones, nitrites, urobilinogen, leukocyte esterase, blood. If blood, protein or leukocytes are positive and determined clinically significant by the investigator, then the participants were returned for an unscheduled visit for microscopic examination. Laboratory abnormality events were graded according to NCI CTCAE v5.0; grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening consequences and grade 5=death. Number of participants who had urinalysis parameter abnormality Grade 3 to 4 are reported in this outcome measure. Number of participants with non-zero laboratory abnormalities are reported in this outcome measure.

    Time frame: Baseline (Day 1) up to End of treatment visit (within 7 days of treatment) [approximately maximum up to 7 weeks]

07

Results

Posted Feb 10, 2025

Participant flow

Participant flow — Overall Study
MilestoneRimegepant 25 mgRimegepant 75 mgPlacebo
Started267268268
Efficacy analysis set (as randomized)238238230
Safety analysis set (as treated)239238229
Completed237238230
Not completed303038
Withdrew: Randomized but not treated293038
Withdrew: Lost to follow-up100

Outcome measures

PrimaryPercentage of Participants Who Had Freedom From Pain at 2 Hours Post-Dose

Pain freedom at 2 hours post-dose was defined as having a pain intensity of none at that time point. Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (no pain) were considered to have freedom from pain. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in Statistical Analysis Plan (SAP).

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Had Freedom From Pain at 2 Hours Post-Dose
Percentage of participantsRimegepant 25 mgRimegepant 75 mgPlacebo
Percentage of Participants Who Had Freedom From Pain at 2 Hours Post-Dose21.0 (15.8 to 26.2)32.4 (26.4 to 38.3)13.0 (8.7 to 17.4)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Mantel Haenszel · p = <0.0001 · Adjusted percentage difference: 19.4 · 95% CI 12.0 to 26.8Adjusted percentage difference (rimegepant 75 mg - placebo) stratified by randomization stratum with Mantel-Haenszel weighting.
SecondaryPercentage of Participants With Pain Relief at 2 Hours Post-Dose

Pain relief at 2 hours post-dose was defined as a pain intensity of none or mild at that time point. Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Pain Relief at 2 Hours Post-Dose
Percentage of participantsRimegepant 25 mgRimegepant 75 mgPlacebo
Percentage of Participants With Pain Relief at 2 Hours Post-Dose66.8 (60.8 to 72.8)79.0 (73.8 to 84.2)56.5 (50.1 to 62.9)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Mantel Haenszel · p = <0.0001 · Adjusted percentage difference: 22.7 · 95% CI 14.5 to 30.9Adjusted percentage difference (rimegepant 75 mg - placebo) stratified by randomization stratum with Mantel-Haenszel weighting.
SecondaryPercentage of Participants Who Had Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-Dose

MBS freedom was defined as MBS reported before dosing that was absent post-dose. MBS included nausea, photophobia, or phonophobia. MBS were measured using a binary scale as 0= absent, 1= present. Participants who had score of 0 (MBS absent) were considered to have freedom from MBS. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Had Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-Dose
Percentage of participantsRimegepant 25 mgRimegepant 75 mgPlacebo
Percentage of Participants Who Had Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-Dose53.4 (47.0 to 59.7)65.1 (59.1 to 71.2)50.4 (44.0 to 56.9)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Mantel Haenszel · p = 0.0011 · Adjusted percentage difference: 14.8 · 95% CI 5.9 to 23.6Adjusted percentage difference (rimegepant 75 mg- placebo) stratified by randomization stratum with Mantel-Haenszel weighting.
SecondaryPercentage of Participants With Ability to Function Normally at 2 Hours Post-Dose

Functional disability was defined as a functional disability level of mildly impaired, severely impaired, or required bedrest. Participants rated the level of disability they perceived as a result of their migraine in performing normal actions using following level of severity: normal function, mild impairment, severe impairment, or required bedrest. Percentage of participants with a response of "normal function" at the 2 hours post-dose were reported in this outcome measure. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Ability to Function Normally at 2 Hours Post-Dose
Percentage of participantsRimegepant 25 mgRimegepant 75 mgPlacebo
Percentage of Participants With Ability to Function Normally at 2 Hours Post-Dose36.0 (29.9 to 42.1)45.5 (39.0 to 51.9)26.9 (21.1 to 32.7)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Mantel Haenszel · p = <0.0001 · Adjusted percentage difference: 18.8 · 95% CI 10.1 to 27.4Adjusted percentage difference (rimegepant 75 mg- placebo) stratified by randomization stratum with Mantel-Haenszel weighting.
SecondaryPercentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-Dose

Sustained Pain relief from 2 to 24 hours post-dose was defined as a pain intensity of none or mild at all time points from 2 to 24 hours post-dose. Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (with no pain) through 2 to 24 hours post-dose were considered to have sustained pain relief. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

Time frame:
2 to 24 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-Dose
Percentage of participantsRimegepant 25 mgRimegepant 75 mgPlacebo
Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-Dose48.3 (42.0 to 54.7)63.4 (57.3 to 69.6)31.7 (25.7 to 37.8)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Mantel Haenszel · p = <0.0001 · Adjusted percentage difference: 31.7 · 95% CI 23.2 to 40.3Adjusted percentage difference (rimegepant 75 mg- placebo) stratified by randomization stratum with Mantel-Haenszel weighting.
SecondaryPercentage of Participants Who Used Rescue Medication Within 24 Hours Post-Dose

Percentage of participants who used rescue medications within 24 hours of administration of study drug were reported in this outcome measure. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

Time frame:
Within 24 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants Who Used Rescue Medication Within 24 Hours Post-Dose
Percentage of participantsRimegepant 25 mgRimegepant 75 mgPlacebo
Percentage of Participants Who Used Rescue Medication Within 24 Hours Post-Dose25.2 (19.7 to 30.7)19.7 (14.7 to 24.8)39.3 (33.0 to 45.6)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Mantel Haenszel · p = <0.0001 · Adjusted percentage difference: -19.7 · 95% CI -27.8 to -11.6Adjusted percentage difference (rimegepant 75 mg- placebo) stratified by randomization stratum with Mantel-Haenszel weighting.
SecondaryPercentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-Dose

Sustained pain relief from 2 to 48 hours post-dose was defined as a pain intensity of none or mild at all time points from 2 to 48 hours post-dose. Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (with no pain) through 2 to 48 hours post-dose were considered to have sustained pain relief. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

Time frame:
2 to 48 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-Dose
Percentage of participantsRimegepant 25 mgRimegepant 75 mgPlacebo
Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-Dose42.0 (35.7 to 48.3)60.5 (54.3 to 66.7)27.4 (21.6 to 33.2)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Mantel Haenszel · p = <0.0001 · Adjusted percentage difference: 33.1 · 95% CI 24.7 to 41.6Adjusted percentage difference (rimegepant 75 mg- placebo) stratified by randomization stratum with Mantel-Haenszel weighting.
SecondaryPercentage of Participants With Absence of Photophobia at 2 Hours Post-Dose

Photophobia (sensitivity to light) status was measured as absent or present in the electronic diary (eDiary). Freedom from photophobia was defined as photophobia absent. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Absence of Photophobia at 2 Hours Post-Dose
Percentage of participantsRimegepant 25 mgRimegepant 75 mgPlacebo
Percentage of Participants With Absence of Photophobia at 2 Hours Post-Dose45.1 (37.4 to 52.7)59.1 (51.5 to 66.8)49.0 (41.1 to 56.9)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Mantel Haenszel · p = 0.0707 (P-value \> 0.05; therefore, all secondary outcome measures listed after this outcome measure in the hierarchy were not tested.) · Adjusted percentage difference: 10.1 · 95% CI -0.9 to 21.1Adjusted percentage difference (rimegepant 75 mg- placebo) stratified by randomization stratum with Mantel-Haenszel weighting.
SecondaryPercentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-Dose

Sustained pain freedom from 2 to 24 hours post-dose was defined as a pain intensity of none at all time points from 2 to 24 hours post-dose. Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (with no pain) through 2 to 24 hours post-dose were considered to have sustained pain freedom. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

Time frame:
2 to 24 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-Dose
Percentage of participantsRimegepant 25 mgRimegepant 75 mgPlacebo
Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-Dose13.9 (9.5 to 18.3)23.1 (17.8 to 28.5)6.5 (3.3 to 9.7)
SecondaryPercentage of Participants With Freedom of Phonophobia at 2 Hours Post-Dose

Phonophobia (sensitivity to sound) status was measured as absent or present in the eDiary. Freedom from phonophobia was defined as phonophobia absent. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Freedom of Phonophobia at 2 Hours Post-Dose
Percentage of participantsRimegepant 25 mgRimegepant 75 mgPlacebo
Percentage of Participants With Freedom of Phonophobia at 2 Hours Post-Dose55.0 (46.4 to 63.5)66.7 (57.8 to 75.6)50.0 (40.6 to 59.4)
SecondaryPercentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-Dose

Sustained pain freedom from 2 to 48 hours post-dose was defined as a pain intensity of none at all time points from 2 to 48 hours post-dose. Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (with no pain) through 2 to 48 hours post-dose were considered to have sustained pain freedom. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

Time frame:
2 to 48 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-Dose
Percentage of participantsRimegepant 25 mgRimegepant 75 mgPlacebo
Percentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-Dose11.8 (7.7 to 15.9)21.4 (16.2 to 26.6)6.1 (3.0 to 9.2)
SecondaryPercentage of Participants With Freedom From Nausea at 2 Hours Post Dose

Nausea status was measured as absent or present in the eDiary. Freedom from nausea was defined as nausea absent. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Freedom From Nausea at 2 Hours Post Dose
Percentage of participantsRimegepant 25 mgRimegepant 75 mgPlacebo
Percentage of Participants With Freedom From Nausea at 2 Hours Post Dose68.4 (59.2 to 77.6)73.7 (65.1 to 82.4)62.6 (52.7 to 72.6)
SecondaryPercentage of Participants With Pain Relapse From 2 to 48 Hours Post-Dose

Pain relapse from 2 to 48 hours post-dose was defined as pain intensity of mild, moderate, or severe at any time point post-dose after 2 hours post-dose for the subset of participants with pain intensity of none at 2 hours post-dose. Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eDiary. Formal statistical hypothesis testing was planned only for rimegepant 75 mg group with controlling type 1 error by the prespecified hierarchical gate-keeping procedure. For rimegepant 25 mg, no formal statistical hypothesis testing was conducted for any outcome measures as pre-specified in SAP.

Time frame:
2 to 48 hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-Dose
Percentage of participantsRimegepant 25 mgRimegepant 75 mgPlacebo
Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-Dose44.0 (30.2 to 57.8)33.8 (23.2 to 44.3)53.3 (35.5 to 71.2)
SecondaryNumber of Participants With Adverse Events (AEs) by Intensity

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. AE intensity included mild, moderate and severe. Mild AE is defined as AEs which is usually transient and may require only minimal treatment or therapeutic intervention. The event were not generally interfered with usual activities of daily living. Moderate AE is defined as AEs which is usually alleviated with additional specific therapeutic intervention. The event interfered with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the participants. Severe AE is defined as AE that interrupts with usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.

Time frame:
From the day of signing informed consent up to end of treatment visit (approximately maximum up to 11 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) by Intensity
ParticipantsRimegepant 25 mgRimegepant 75 mgPlacebo
Mild161912
Moderate133
Severe000
SecondaryNumber of Participants With Serious AEs

A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect in the off spring who received rimegepant were considered an important medical event.

Time frame:
From the day of signing informed consent up to end of treatment visit (approximately maximum up to 11 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Serious AEs
ParticipantsRimegepant 25 mgRimegepant 75 mgPlacebo
Number of Participants With Serious AEs010
SecondaryNumber of Participants With Grade 3 to 4 Laboratory Test Abnormalities- Hematology

Laboratory test abnormalities in hematology included: Eosinophils, Hemoglobin (high, low), Lymphocytes (high, low), Neutrophils, Platelets, White blood cell count (high, low). Laboratory abnormality events were graded according to National Cancer Institute Common Terminology Criteria For Adverse Events (NCI CTCAE) v5.0; grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening consequences and grade 5=death. Number of participants who had hematology parameter abnormality Grade 3 to 4 are reported in this outcome measure. Number of participants with non-zero laboratory abnormalities were reported in this outcome measure.

Time frame:
Baseline (Day 1) up to End of treatment visit (within 7 days of treatment) [approximately maximum up to 7 weeks]
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 to 4 Laboratory Test Abnormalities- Hematology
ParticipantsRimegepant 25 mgRimegepant 75 mgPlacebo
Number of Participants With Grade 3 to 4 Laboratory Test Abnormalities- Hematology100
SecondaryNumber of Participants With Grade 3 to 4 Laboratory Test Abnormalities- Serum Chemistry

Laboratory test abnormalities in serum chemistry included: alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, Bilirubin (total), calcium (high, low), cholesterol (total), creatine kinase, creatinine, estimated glomerular filtration rate (eGFR), Modification of Diet in Renal Disease (MDRD), glucose, (high, low), lactate dehydrogenase low density lipoprotein (LDL) cholesterol (fasting, non-fasting), potassium (high, low), sodium (high, low), triglycerides (fasting, non-fasting), uric acid. Laboratory abnormality events were graded according to NCI CTCAE v5.0; grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening consequences and grade 5=death. Number of participants who had serum chemistry parameter abnormality Grade 3 to 4 are reported in this outcome measure. Number of participants with non-zero laboratory abnormalities are reported in this outcome measure.

Time frame:
Baseline (Day 1) up to End of treatment visit (within 7 days of treatment) [approximately maximum up to 7 weeks]
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 to 4 Laboratory Test Abnormalities- Serum Chemistry
ParticipantsRimegepant 25 mgRimegepant 75 mgPlacebo
Creatine kinase200
LDL cholesterol434
Triglycerides101
SecondaryNumber of Participants With Grade 3 to 4 Laboratory Test Abnormalities- Urinalysis

Laboratory test abnormalities in urinalysis included: Urine glucose, Urine protein, pH, specific gravity, ketones, nitrites, urobilinogen, leukocyte esterase, blood. If blood, protein or leukocytes are positive and determined clinically significant by the investigator, then the participants were returned for an unscheduled visit for microscopic examination. Laboratory abnormality events were graded according to NCI CTCAE v5.0; grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life-threatening consequences and grade 5=death. Number of participants who had urinalysis parameter abnormality Grade 3 to 4 are reported in this outcome measure. Number of participants with non-zero laboratory abnormalities are reported in this outcome measure.

Time frame:
Baseline (Day 1) up to End of treatment visit (within 7 days of treatment) [approximately maximum up to 7 weeks]
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 to 4 Laboratory Test Abnormalities- Urinalysis
ParticipantsRimegepant 25 mgRimegepant 75 mgPlacebo
Number of Participants With Grade 3 to 4 Laboratory Test Abnormalities- Urinalysis001

Adverse events

Collected over From the day of signing informed consent up to end of treatment visit (approximately maximum up to 11 weeks). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rimegepant 25 mg0/239 (0%)0/239 (0%)3/239 (1.3%)
Rimegepant 75 mg0/238 (0%)1/238 (0.4%)3/238 (1.3%)
Placebo0/229 (0%)0/229 (0%)2/229 (0.9%)
Most frequent serious events
Most frequent serious events
EventRimegepant 25 mgRimegepant 75 mgPlacebo
Suicidal ideationPsychiatric disorders0/2391/2380/229
Most frequent other events
Most frequent other events
EventRimegepant 25 mgRimegepant 75 mgPlacebo
NasopharyngitisInfections and infestations3/2393/2382/229

Baseline characteristics

Safety analysis set consisted of participants in the enrolled analysis set (participants who signed an informed consent form and were assigned a participant identification number) and who had taken the study drug (rimegepant 25 mg, rimegepant 75 mg, or placebo). One participant who was randomized to the placebo group received rimegepant 25 mg. This participant in safety analysis set was included in rimegepant 25 mg arm and not in placebo arm.

Age, Continuous
Age, Continuous(Years)Rimegepant 25 mgRimegepant 75 mgPlaceboTotal
Mean40.3 ± 10.4940.5 ± 11.2541.4 ± 11.2540.8 ± 10.99
Sex: Female, Male
Sex: Female, Male(Participants)Rimegepant 25 mgRimegepant 75 mgPlaceboTotal
Female188189173550
Male514956156
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Rimegepant 25 mgRimegepant 75 mgPlaceboTotal
Count of participants———0
08

Study locations

50 sites
  • Tokyo Dental College Ichikawa General Hospital
    Ichikawa-shi, Chiba 272-8513, Japan
  • Medical Corporation Seikokai Takanoko Hospital
    Matsuyama-shi, Ehime 790-0925, Japan
  • Jinnouchi Neurosurgical Clinic
    Kasuga-shi, Fukuoka 816-0802, Japan
  • Ikeda Neurosurgical Clinic
    Kasuga-shi, Fukuoka 816-0824, Japan
  • SUBARU Health Insurance Society Ota Memorial Hospital
    Ota-shi, Gunma 373-8585, Japan
  • DOI CL Intern. Med./Neurol.
    Hiroshima-shi, Hiroshima 730-0031, Japan
  • Japanese Red Cross Asahikawa Hospital
    Asahikawa-shi, Hokkaido 070-8530, Japan
  • Higashi Sapporo Neurology and Neurosurgery Clinic
    Sapporo-shi, Hokkaido 003-0003, Japan
  • Nakamura Memorial Hospital
    Sapporo-shi, Hokkaido 060-8570, Japan
  • Nishinomiya Municipal Central Hospital
    Nishinomiya-shi, Hyogo 663-8014, Japan
  • Konan Medical Center
    Kobe-shi, Hyōgo 658-0064, Japan
  • Mito Kyodo General Hospital
    Mito-shi, Ibaraki 310-0015, Japan
  • Kijima Neurosurgery Clinic
    Kahoku-gun, Ishikawa 929-0342, Japan
  • Iwate Med. Univ. Uchimaru MC
    Morioka-shi, Iwate 020-8505, Japan
  • Atsuchi Neurosurgery Hospital
    Kagoshima-shi, Kagoshima 892-0842, Japan
  • Tanaka Neurosurgical Clinic
    Kagoshima-shi, Kagoshima 892-0844, Japan
  • St. Marianna Univ. Hospital
    Kawasaki-shi, Kanagawa 216-8511, Japan
  • Fujitsu Clinic
    Nakahara, Kanagawa 211-8588, Japan
  • Saiseikai Kumamoto Hospital
    Kumamoto-shi, Kumamoto 861- 4193, Japan
  • Kyoto Okamoto Memorial Hospital
    Kumiyama-cho, Kyoto 613-0034, Japan
  • University Hospital Kyoto Prefectural University of Medicine
    Kyoto-shi, Kyoto 602-8566, Japan
  • Ishikawa Clinic
    Sakyo-ku, Kyoto 606-0851, Japan
  • Tatsuoka Neurology Clinic
    Shimogyo-ku, Kyoto 600-8811, Japan
  • Atago Hospital
    Kochi-shi, Kōchi 780-0051, Japan
  • Umenotsuji Clinic
    Kochi-shi, Kōchi 780-8011, Japan
  • Narikawa Neurological Clinic
    Izumi-ku, Miyagi 981-3126, Japan
  • Sendai Headache and Neurology Clinic, Medical Corporation
    Sendai-shi, Miyagi 982-0014, Japan
  • Ooba CL Neurosurg. & Headache
    Oita-shi, Oita 870-0831, Japan
  • Makabe Clinic
    Okayama-shi, Okayama 700-0964, Japan
  • Okayama City General Medical Center Okayama City Hospital
    Okayama-shi, Okayama 700-8557, Japan
  • Tominaga Clinic
    Naniwa-ku, Osaka 556-0015, Japan
  • Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-kofukai
    Osaka-city, Osaka 530-8480, Japan
  • Kindai University Hospital
    Osakasayama-shi, Osaka 589-8511, Japan
  • Takase Intern. Med. Clinic
    Toyonaka-shi, Osaka 560-0012, Japan
  • Saitama Medical University Hospital
    Iruma-gun, Saitama 350-0495, Japan
  • JRC Shizuoka Hospital
    Shizuoka-shi, Shizuoka 420-0853, Japan
  • Dokkyo Medical Univ. Hosp.
    Shimotsuga-gun, Tochigi 321-0293, Japan
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo 113-8431, Japan
  • Tokai university hachioji hospital
    Hachioji-shi, Tokyo 192-0032, Japan
  • Shinagawa Strings Clinic
    Minato-ku, Tokyo 108-0075, Japan
  • Kitasato University Kitasato Institute Hospital
    Minato-ku, Tokyo 108-8642, Japan
  • USUDA CLINIC for internal medicine
    Setagaya-ku, Tokyo 156-0043, Japan
  • Tokyo Headache Clinic
    Shibuya-Ku, Tokyo 151-0051, Japan
  • Fukuuchi Pain Clinic
    Shinjuku-ku, Tokyo 160-0017, Japan
  • Keio University Hospital
    Shinjuku-ku, Tokyo 160-8582, Japan
  • Nishiogi Pain Clinic
    Suginami-ku, Tokyo 167-0054, Japan
  • Suzuki Kei Yasuragi clinic
    Tachikawa-city, Tokyo 190-0001, Japan
  • Sakura Neuro Clinic
    Toyama-shi, Toyama 930-0803, Japan
  • Nagamitsu Clinic
    Hofu-shi, Yamaguchi 747-0802, Japan
  • Nagaseki Headache Clinic
    Kai-shi, Yamanashi 400-0124, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jan 2024, 17 months.

Results were first posted in Feb 2025, 1 year after primary completion.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 17 months is close to that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2022
First posted
Jun 1, 2022
StartActual
Aug 9, 2022
Primary completionActual
Jan 19, 2024
CompletionActual
Jan 19, 2024
Results first posted
Feb 10, 2025
Last update
Mar 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05399459
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 1, 2022
Start date
Aug 9, 2022
Primary completion
Jan 19, 2024
Completion
Jan 19, 2024
Results posted
Feb 10, 2025
Last update
Mar 7, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimegepant

Start the discussion